| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 71,735 | 56,663 |
| Net increase in cash and cash equivalents and restricted cash | 28,623 | 16,791 |
| Cash and cash equivalents at beginning of period | 58,815 | - |
| Cash and cash equivalents at end of period | 87,438 | - |
Fortress Biotech, Inc. (FBIOP)
Fortress Biotech, Inc. (FBIOP)